Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 39

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 39
---
 technological innovations or new therapies that compete with our potential products;

    ·
    the loss of key employees;

    ·
    general and industry-specific economic conditions that may affect our research and development expenditures;

    ·
    changes in the structure of healthcare payment systems;

    ·
    issuance of new shares of common stock from raising additional capital, which may not be available on acceptable terms, or at all; and

    ·
    period-to-period fluctuations in our financial results.

Moreover, the stock markets in general have experienced
substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations
may also adversely affect the trading price of our common stock.

In the past, following periods of volatility in the
market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies.
Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly
harm our financial position.

Our share price could decline as a result of short
sales.

When an investor sells stock that he does not own,
it is known as a short sale. The seller, anticipating that the price of the stock will go down, intends to buy stock to cover his/her
sale at a later date. If the price of the stock goes down, the seller will profit to the extent of the difference between the price at
which he originally sold it less his later purchase price. Short sales enable the seller to profit in a down market. Short sales could
place significant downward pressure on the price of our common stock. Penny stocks which do not trade on an exchange, such as our common
stock, are particularly susceptible to short sales.

We may issue preferred stock, and the terms of
such preferred stock may reduce the value of our common stock. 

We are authorized to issue up to a total of 5,000,000
shares of preferred stock in one or more series, of which, 4,300,000 have been undesignated as of December 31, 2024. Our Board of Directors
may determine whether to issue shares of preferred stock without further action by holders of our common stock. If we issue shares of
preferred stock, it could affect the rights or reduce the value of our common stock. In particular, specific rights granted to future
holders of preferred stock could be used to restrict our ability to merge with or sell our assets to a third party. These terms may include
voting rights